Recombinant human thrombopoietin in pediatric allogeneic hematopoietic stem cell transplantation: Clinical insights and future directions.

The cohort study by Li et al provides timely and clinically relevant evidence on the use of recombinant human thrombopoietin (rhTPO) in pediatric allogeneic hematopoietic stem cell transplantation. The authors report enhanced platelet engraftment and a favorable safety profile, particularly in younger children aged 0-9 years. This age-dependent difference not only highlights the physiological responsiveness of early hematopoietic environments to rhTPO but also raises important questions about tailoring supportive therapies across pediatric age groups. While the findings are promising, the lack of a control group and single-center limitations warrant further multicenter, long-term investigations. Nevertheless, the study lays a compelling foundation for integrating rhTPO more broadly into pediatric transplant protocols and for advancing individualized post-transplant care.